Trump Criticizes EU’s €120 Million Fine on Elon Musk’s X Platform 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
South Korea Extends Bond Market Stabilization Measures Amid Rising Financial Risks 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Trump Signals Two Final Candidates for Fed Chair, Calls for Presidential Input on Interest Rates 
Thailand Vows Continued Military Action Amid Cambodia Border Clash Despite Trump Ceasefire Claim 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
Supreme Court to Weigh Trump’s Power to Remove FTC Commissioner 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Australia’s Labour Market Weakens as November Employment Drops Sharply 
Colombia’s Clan del Golfo Peace Talks Signal Mandatory Prison Sentences for Top Leaders 
Tunisia Protests Grow as Opposition Unites Against President Kais Saied’s Rule 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
Trump Administration Fuel-Efficiency Rollback Could Raise Long-Term Costs for U.S. Drivers 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
